Comparative Immunogenicity of mRNA and Protein Subunit Vaccine Platforms

Abstract

The rapid, parallel authorization of mRNA and adjuvanted protein subunit vaccines against SARS-CoV-2 created an unusually informative natural comparison between two mechanistically distinct approaches to eliciting protective immunity against the same structurally defined spike antigen. This article synthesizes the published immunogenicity, efficacy, and durability literature for both platforms, tracing the mRNA approach from nucleoside-modification chemistry and lipid-nanoparticle delivery through to clinical antibody and T cell data, and the protein subunit approach from saponin-based adjuvant biology through to its own clinical immunogenicity readouts. Phase 3 trials reported efficacy of 95% for BNT162b2, 94.1% for mRNA-1273, and 89.7% for NVX-CoV2373 against symptomatic COVID-19, with overlapping confidence intervals; both platforms elicited neutralizing antibody titers exceeding those seen in convalescent serum and drove comparably Th1-skewed cellular responses despite activating innate immunity through entirely different molecular mechanisms. We give particular weight to the evidentiary limits of cross-trial comparison, the asymmetry in published durability and germinal-centre data between the two platforms, and the practical manufacturing and reactogenicity tradeoffs that distinguish them. Read together, the evidence supports both platforms as independently validated, comparably effective, and mechanistically complementary routes to protective immunity, an outcome we treat as a useful redundancy for future vaccine development rather than a contest with a clear winner.